Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,112 | $5,822 | $5,992 | $7,811 |
| % Growth | -12.2% | -2.8% | -23.3% | – |
| Cost of Goods Sold | $1,213 | $1,631 | $2,289 | $1,600 |
| Gross Profit | $3,899 | $4,191 | $3,703 | $6,212 |
| % Margin | 76.3% | 72% | 61.8% | 79.5% |
| R&D Expenses | $2,615 | $2,409 | $1,740 | $1,788 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8,749 | $9,261 | $12,209 | $15,593 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10,215 | $6,138 | $9,669 | $6,878 |
| Operating Expenses | $21,579 | $17,809 | $23,618 | $24,260 |
| Operating Income | -$17,680 | -$13,617 | -$19,916 | -$18,048 |
| % Margin | -345.8% | -233.9% | -332.4% | -231.1% |
| Other Income/Exp. Net | $3,361 | $5,454 | -$122 | $9,061 |
| Pre-Tax Income | -$14,319 | -$8,163 | -$20,038 | -$8,987 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,319 | -$8,163 | -$20,038 | -$8,987 |
| % Margin | -280.1% | -140.2% | -334.4% | -115% |
| EPS | -3.34 | -6.35 | -9.68 | -8.25 |
| % Growth | 47.4% | 34.4% | -17.3% | – |
| EPS Diluted | -3.34 | -6.35 | -9.68 | -8.25 |
| Weighted Avg Shares Out | 8,026 | 1,286 | 2,070 | 1,089 |
| Weighted Avg Shares Out Dil | 8,026 | 2,176 | 2,070 | 1,089 |
| Supplemental Information | – | – | – | – |
| Interest Income | $372 | $515 | $14 | $0 |
| Interest Expense | $561 | $536 | $596 | $369 |
| Depreciation & Amortization | $2,944 | $3,415 | $5,716 | $6,878 |
| EBITDA | -$10,814 | -$4,212 | -$13,726 | -$1,740 |
| % Margin | -211.5% | -72.3% | -229.1% | -22.3% |